Company intelligence / Profile preview
ReCode Therapeutics
Menlo Park, California, United Statesrecodetx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
ReCode’s lead programs—RCT1100 for primary ciliary dyskinesia and RCT2100 for cystic fibrosis—are inhaled mRNA-based therapies using the SORT LNP platform. Both are designed for patient populations with no effective existing treatments. The company has raised significant funding ($260M Series B as of September 2023), has been recognized by Fierce Biotech’s “Fierce15” list and Nature’s “Seven Technologies to Watch,” but specific clinical results have not yet been published or detailed in public sources.
- Therapeutic areas
- GastroenterologyRheumatologyRare DiseasesNeurologyInfectious Diseases
- Modalities
- mRNA therapeuticsGene correction therapiesLipid nanoparticle (LNP) delivery systems (enabling technology)
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on ReCode Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ReCode Therapeutics.